Order-of-magnitude gap: the company is already serving a demand source whose scale dwarfs its own current business
The model's full reasoning — Q1 2016 call → NOWe need to determine if management describes a mismatch of scale between the company and the demand it is already serving. The key is: the company is already inside a large flow, and management explicitly contrasts its own size with that flow, treating the gap as central. Looking at the transcript: Michael Small mentions "2Ku awarded aircraft over the 1000 mark." He also says "we are making great progress on the increasing volume of STCs, completion of which will keep us on track to exceed our 75 2Ku installation target this year." That's about installations. He also says "we have massive momentum with 2Ku" and lists many airline deals. But does he explicitly contrast the company's size with the scale of what it serves? He says "we are off to an amazing start" and "record revenue" but not a specific contrast like "we have only captured a tiny fraction of the market." He does say "we have 1000 2Ku awarded aircraft" but that's a backlog, not necessarily a contrast. He also says "we are now operating on four continents" and "we are seeing increasing activity." But the question is about a mismatch of scale: the company is small relative to the flow it is already inside. Management might say something like "we have only installed a small fraction of the awarded aircraft" or "the potential is many times our current revenue." I don't see that explicit contrast. Norm mentions "CA rest of world backlog stands at over 600 awarded but not yet installed aircraft" but again that's a backlog. The question asks: does management convey that the company is currently supplying, serving, or participating in something whose size is enormous relative to the company's own current business? They talk about 1000 aircraft, but the company's current business is also large. They have 2500 North American aircraft online, plus BA, etc. So the company is not tiny relative to that. The key is whether management draws a contrast that even a modest further share would make it several times bigger. I don't see that. They talk about growth but not a specific disproportion. They mention "we have massive momentum" but not "we are a small player in a huge market." They also mention "we have a lot of business out there" but that's generic. The answer is likely NO. Also, the question requires that management itself draws the size contrast and treats it as the point. I don't see that.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| GDRX | GoodRx Holdings, Inc. | Q2 2022 | 2022-08-08 | F |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| IRTC | iRhythm Technologies, Inc. | Q1 2022 | 2022-05-07 | C+ |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| RELY | Remitly Global, Inc. | Q4 2021 | 2022-03-02 | B |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| HSTM | HealthStream, Inc. | Q3 2017 | 2017-10-24 | C |
HROW · Q4 2021 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...YES The transcript shows management describing Harrow as already inside the large cataract surgery market (4.5–6 million procedures annually) with real, present-tense participation: thousands of customer relationships, shipping north of two million sterile ophthalmic units last year, and touching roughly one million cataract surgeries. They explicitly contrast this scale against 2021 revenues of $72.5 million, noting that even a modest share of the pass-through-eligible market (1 million procedures × premium pricing) would produce “a big number” and drive revenues “more than double” in the near term. They treat the current business as only the “earliest sliver” of what they are already positioned inside, with the binding question being how much of the existing flow they can capture rather than whether the flow exists. This meets both criteria. The answer is YES. The transcript shows management describing Harrow as already inside the large cataract surgery market (4.
WRBY · Q1 2024 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...YES The transcript explicitly states that the company is already inside the optical industry with real business (245 stores serving customers, 83% of stores offering exams, 2.36 million active customers, and growing revenue from glasses, contacts, and exams). Management then draws the size contrast directly, noting that even the longer 900-store target "would still represent a small fraction of the 45,000 optical shops in the U.S." and that over 50% of major metro areas have only one store.
HSTM · Q3 2017 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...**YES** Management describes the company already being inside a much larger flow of activity (the 80 million-person healthcare workforce, of which 4.6 million are in post-acute settings) and explicitly treats the scale mismatch as the central point. They note their strong sales team is already a “steady contributor” to 4.